Johnson & Johnson Explores $20B Orthopedics Unit Sale, Invests $1B in Cell Therapy Plant
Johnson & Johnson is preparing to sell its DePuy Synthes orthopedics unit, potentially valued at over $20 billion, with private equity firms and rival device makers circling. It will also invest $1 billion in a Montgomery County, Pennsylvania cell therapy facility, creating 500 manufacturing and 4,000 construction jobs.
1. Potential Sale of DePuy Synthes Orthopedics Unit
Johnson & Johnson is assembling financial documents and engaging with private equity firms and rival medical device players as it explores a sale of its DePuy Synthes orthopedics unit, which generated $9.3 billion in sales in 2025 and could fetch over $20 billion. The unit, maker of hip, knee and shoulder implants, is slated for a standalone spinoff within 18–24 months, with the company weighing a tax-free spinoff or sale and expecting material updates by mid-2026.
2. $1B Pennsylvania Cell Therapy Facility Investment
The company will invest $1 billion in a Montgomery County, Pennsylvania cell therapy manufacturing facility, adding over 500 manufacturing roles and 4,000 construction jobs. This expansion is intended to boost biologics production capacity and support growth in high-margin cell therapy treatments.